Phase 2
Completed N=304
A Study of LY2623091 in Participants With High Blood Pressure
Source: ClinicalTrials.gov NCT02194465 ↗Enrolled (actual)
304
Serious AEs
1.0%
Results posted
Jun 2020
Primary outcomePrimary: Change From Baseline to 4 Weeks in Seated Systolic Blood Pressure (SBP) — -0.5; -13.1; -14.6; -14.3 millimeter of mercury (mmHg)
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline to 4 Weeks in Seated Systolic Blood Pressure (SBP) |
-0.5; -13.1; -14.6; -14.3; -11.8; -7.1 | — |
| SECONDARY Change From Baseline to 4 Weeks in Seated Diastolic Blood Pressure (DBP) |
0.5; -5.6; -4.8; -7.1; -6.8; -6.6 | — |
| SECONDARY Change From Baseline to 4 Weeks in 24 Hour Ambulatory Blood Pressure Monitoring (ABPM) |
0.3; -4.9; -11.1; -10.4; -10.4; -6.3 | — |
| SECONDARY Change From Baseline to 4 Weeks in Serum Potassium |
-0.04; 0.10; 0.11; 0.25; 0.10; -0.06 | — |
| SECONDARY Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2623091 |
122; 228; 379; 206 | — |
Eligibility Criteria
Inclusion Criteria
- Have a history of hypertension.
- If participants are naïve to treatment of hypertension, or have not been treated with any antihypertensive medications within the 30 days immediately prior to screening:
- Have seated systolic (SBP) of ≥140 and 5.0 millimoles per liter (mmol/L).
- Have an estimated glomerular filtration rate (eGFR) <50 milliliters/minute/1.73 m^2.
Data sourced from ClinicalTrials.gov (NCT02194465). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.